New cell therapy, Cilta-cel, shows promise in the treatment of multiple myeloma, providing a personalised approach with the ...

The panelist discusses how for managing patients with R/R multiple myeloma, community clinicians should focus on personalized ...

Sanofi has received China’s National Medical Products Administration (NMPA) approval for the use of Sarclisa (isatuximab), ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

Primary results of phase 3 AURIGA study indicated that dual maintenance therapy after transplant led to improved outcomes.

In this video interview, Michael Andreini, president and CEO of the Multiple Myeloma Research Foundation, highlights how the ...

This information is clinically relevant because if a patient continues to have MRD-positive status after treatment with isatuximab-VRd, then a change of therapy may prolong progression-free survival.

Over the past two decades the paradigm of multiple myeloma therapy has changed dramatically from conventional chemotherapy and autologous stem cell transplant (ASCT) to combination regimens of ...

On this World Cancer Day, Chris Vogelsang, a cancer survivor from upstate New York, is celebrating his recovery thanks to a ...

Days after the European Commission (EC) granted approval, the UK’s Medicines and Healthcare Regulatory Agency (MHRA) has ...

More Than 20 Alpha Therapies Are In Clinical Trials Says KUICK RESEARCH In Recent PublicationDelhi, Jan. 29, 2025 (GLOBE ...